The present invention relates to an improved thermostable spray dried rotavirus vaccine formulation and the process of preparing the same. More specifically the present invention discloses thermostable liquid, powder or granule-based rotavirus vaccine prepared using the spray drying process, such that the said vaccine has improved heat-stability, ease-of-use, ease-of-transportation and affordability features with significantly better chance of being adopted in developing and low income country's vaccination program.

The present invention provides, among other things, methods and compositions of formulating nucleic acid-containing nanoparticles for efficient delivery of payload in vivo such that the method and compositions can be used to generate mRNA vaccines.

An expression system, comprising: a first nucleic acid molecule having a cell-specific promoter; a second nucleic acid molecule which encodes a transcriptional activator; a third nucleic acid molecule having a first recognition sequence of the transcriptional activator; a fourth nucleic acid molecule having a first promoter and a first regulatory element; a fifth nucleic acid molecule which encodes a first regulatory protein; a sixth nucleic acid molecule having a second recognition sequence of the transcriptional activator; a seventh nucleic acid molecule having a second promoter and a second regulatory element; an eighth nucleic acid molecule which encodes a second regulatory protein; as well as a ninth nucleic acid molecule which is configured to conditionally inhibit the expression of the first regulatory protein, and a tenth nucleic acid molecule which is configured to conditionally inhibit the expression of the second regulatory protein; the first regulatory element is adapted to inhibit the function of the first promoter by means of binding to the second regulatory protein, and the second regulatory element is adapted to inhibit the function of the second promoter by means of binding to the first regulatory protein.

The disclosure relates to Zika virus infection and the treatment thereof. The invention includes ribonucleic acid compositions, as well as methods of using the compositions for treating and preventing Zika virus infection.

Compositions are provided that contain sporulated coccidial oocysts, wherein the compositions are free of antibiotics and comprise formalin at a concentration sufficient to inhibit microbial growth for at least 12 months while maintaining oocyst viability. Methods of preparing such compositions are also provided.

Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.

The present invention is based, in part, on the identification of novel biomarkers, and methods of modulate thereof, for sensitizing cancer cells to T cell-mediated killing.

Disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a homologous prime/boost vaccination strategy, such as adenoviral vectors for use in a homologous prime/boost vaccination strategy.

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes an antigen. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.